

Ophthalmology


Q4 2023

Market Update











The ophthalmology space continued to experience slower deal flow in the fourth quarter, primarily driven by a shortage of practices exploring a potential sale. Many large-scale practices and private equity-backed platforms have delayed transaction processes due to the tight lending environment and increased cost of debt. As credit markets settle down though, Provident expects the constrained supply to abate in 2024 and valuations to rebound to previously elevated levels.

Given the sector's position within its investment lifecycle, many platforms that are four to six years within their hold period will likely launch marketing processes of their own in 2024 to explore partnership options. As this "consolidation of consolidators" theme continues to play out, Provident expects 2024 to be a rebound year for M&A activity within the sector.

Quarterly Transaction Volume



Select Transactions

Month	Acquirer	Target	Physicians	Locations	State
December			4	4	Florida
December			1	1	Connecticut
December			1	1	Florida
November			5	4	Maryland
November			2	1	Georgia

Provident Industry Coverage Team

Eric Major
Managing Director
 (617) 226-4212
 emajor@providenthp.com

Steve Grassa, CFA
Vice President
 (617) 226-4213
 sgrassa@providenthp.com